14th Jan 2021 16:07
PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - Says investee Follica has appointed two veteran biotech executives to its board. Tom Wiggans, former CEO of Dermira, joins as executive chair and Michael Davin, former CEO of Cynosure, joins as an independent member of the board.
Separately, says investee Vor Biopharma, a clinical-stage cell therapy company making engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer, says the US Food & Drug Administration has cleared the company's investigational new drug application for VOR33, an eHSC therapy candidate being developed for the treatment of acute myeloid leukemia. Vor plans to initiate a Phase 1/2a clinical trial for VOR33 in the first half of this year.
Current stock price: 388.50 pence
Year-to-date change: down 2.9%
By Paul McGowan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech